SHIfT (Systolic Heart failure treatment with the If inhibitor ivabradine Trial) is the first study to assess whether heart rate reduction by direct sinus node inhibition can decrease cardiovascular outcomes in patients with chronic heart failure and left ventricular systolic dysfunction.1
[symptomatic patients (NYHA II-IV) in sinus rhythm with heart rate ≥75 bpm]2
[symptomatic patients (NYHA II-IV) in sinus rhythm with heart rate ≥70 bpm]3
Ivabradine is the first innovative drug after more than a decade to improve the prognosis, to reduce hospitalizations, and to improve the quality of life of heart failure patients.
- Swedberg K, et al. Lancet. 2010;376(9744):875-885.
Ivabradine is available under the following brand names: Procoralan®, Coralan®, Corlanor®, Corlentor®, and Coraxan®.